Skip to main content
. 2021 Aug 12;12(8):789. doi: 10.1038/s41419-021-04073-0

Fig. 4. BCL2 family protein or mRNA expression does not predict paclitaxel sensitivity in ovarian cancer.

Fig. 4

a, b Whole-cell lysates (1 × 105 cells) of indicated cell lines, along with different concentrations of purified corresponding standard protein, were blotted with antibodies to BAK, BCLXL, MCL1, and BCL2 (a), or antibodies to PUMA and NOXA (b). The amount of standard proteins are: BAK∆TM (0.19, 0.38, 0.75, 1.50 ng); BCLXL ∆TM (1.0, 2.0, 4.0, and 8.0 ng); MCL1∆TM (1.0, 2.0, 4.0, and 8.0 ng); BCL2∆TM (0.05, 0.10, 0.20, and 0.40 ng); PUMA (0.06, 0.13, 0.25, and 0.50 ng); and NOXA (0.31, 0.63, 1.25, and 2.50 ng). c BCL2 family proteins evaluated in 105 of indicated ovarian cancer cell lines. Data from two independent experiments were shown. d Correlation between protein levels (ng/105 cells) of BAK, BCLXL, MCL1, BCL2, PUMA, and NOXA, respectively, and apoptosis induced by 8 nM paclitaxel. e Correlation of overall survival with an expression of mRNA encoding BAK, BCLXL, MCL1, BCL2, PUMA, and NOXA from TCGA database, respectively. Ovarian cancer patients with paclitaxel treatment but without radiotherapy were selected.